NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Guideline Alliance (UK). Cystic Fibrosis: Diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)
Table 2Summary of McIlwaine 2014
| Study | Limitations | Applicability | Other comments | Inc. costs | Inc. effects | Inc. cost-effectiveness | Uncertainty |
|---|---|---|---|---|---|---|---|
| McIlwaine 2014 | Seriousa,b,c | Partiallyd,e |
| Total medical cost/participant (including equipment cost) over 1 year:
|
| NR | Not assessed |
HFCWO, high frequency chest wall oscillation; NR, not reported; PEP, positive expiratory pressure
- (a)
Absence of detail regarding: cost build up for HFCWO equipment, specific sources of cost data, definition of an exacerbation, perspective and study dates
- (b)
Data in the paper is based on single values, there is no measure of data dispersion
- (c)
The cost of HFCWO equipment has not been annuitised over the equipment lifespan which over estimates the cost of the vest over one year
- (d)
Conference paper with limited details to assess with certainty
- (e)
QALY not used as an outcome measure
- Table 2, Summary of McIlwaine 2014 - Cystic FibrosisTable 2, Summary of McIlwaine 2014 - Cystic Fibrosis
- Table 4, Cost of oscillating and PEP devices - Cystic FibrosisTable 4, Cost of oscillating and PEP devices - Cystic Fibrosis
Your browsing activity is empty.
Activity recording is turned off.
See more...